Clinical Trial Update: MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults [Phase 4]

View source ↗

Summary

This Phase 4 trial compares Symbicort single inhaler therapy to conventional best standard treatment for persistent asthma in adolescents and adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 4 | Status: COMPLETED